Cancer patients’ access to advanced genetic testing is not keeping up with the pace of discovery of targetable mutations and personalised therapies – European Society for Medical Oncology

The ESMO Study on the Availability and Accessibility of Biomolecular Technologies in Oncology in Europe published in Annals of Oncology, reveals that cancer patients’ access to advanced genetic testing is not keeping up with the pace of discovery of targetable mutations and personalised therapies.

Disparities in access were particularly pronounced for recently validated biomarkers or those requiring complex sequencing techniques. The survey results highlight the need for targeted policies to address the gaps in infrastructure and funding for Precision Oncology.

For details: Click here

Source: European Society for Medical Oncology/Linkedin